Lorenzo Vaccaro

Lorenzo Vaccaro

Auto-generated profile, based on publicly available information

Lorenzo Vaccaro

Telethon Institute of Genetics and Medicine (TIGEM), Armenise/Harvard Laboratory of Integrative Genomics, Pozzuoli, Italy

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 December 2024 in European Journal of Human Genetics
Verified
Journal Article
Closed access
PDF file
LMLucia Micale
Lucia Micale
AVAikaterini Vourlia
Aikaterini Vourlia
CFCarmela Fusco
Carmela Fusco
RPRiccardo Pracella
Riccardo Pracella
DKDimitrios-Christoforos Karagiannis
Dimitrios-Christoforos Karagiannis
MCMarco Castori
Marco Castori

30 April 2025 in Journal of Human Genetics
Verified
Journal Article
Closed access
PDF file
MCMarco Castori
Marco Castori
SMSandra Mastroianno
Sandra Mastroianno
AFAndrea Fontana
Andrea Fontana
SMSilvia Morlino
Silvia Morlino
GNGrazia Nardella
Grazia Nardella
GSGiuseppe Di Stolfo
Giuseppe Di Stolfo

7 March 2024 in Journal of Human Genetics
Verified
Journal Article
Closed access
PDF file
SMSilvia Morlino
Silvia Morlino
LVLorenzo Vaccaro
Lorenzo Vaccaro
MLMaria Pia Leone
Maria Pia Leone
GNGrazia Nardella
Grazia Nardella
LBLuigi Bisceglia
Luigi Bisceglia
LMLucia Micale
Lucia Micale

9 October 2026 in Nature Communications
Verified
Journal Article
Open access
PDF file
LVLorenzo Vaccaro
Lorenzo Vaccaro
RSRosa De Santis
Rosa De Santis
FPFrancesco Panariello
Francesco Panariello
AGAntonio Grimaldi
Antonio Grimaldi
GGGennaro Gandolfo
Gennaro Gandolfo
DCDavide Cacchiarelli
Davide Cacchiarelli
Predicting the pathogenic effect of rare genetic variants is significantly hampered by the limited cohort of diagnosed patients and the difficulty in functionally evaluating the effect of existing and novel variants. To address this issue, we leveraged a protein Multiplexed Assay of Variants Effect (MAVE) to functionally assess the effect of ~ 2200 missense variants of the TP63 gene, some of which cause autosomal dominant developmental disorders. The activity of each variant was measured using an optimized fibroblast-to-keratinocyte conversion protocol, and a subset of mutants was validated through multiple orthogonal biochemical and genomics functional assays to assess consistency and robustness. To systematically expand MAVEs beyond predefined assay, we here introduce SCRAMseq (Single Cell RNAseq Associated with MAVEs by sequencing). This generalizable platform leverages full-length scRNAseq for high-throughput, single-cell genotype-to-phenotype mapping. We validate SCRAMseq across different experimental and genetic contexts to demonstrate its reproducibility and accuracy. SCRAMseq provides a robust and versatile workflow poised to accelerate the discovery and dissection of gene variant effects on any potential disease-driving pathway, thereby significantly broadening MAVEs applicability to virtually any possible disease-driving gene.